Loading
A phase 2 trial of FPI-2265, Olaparib in prostate cancer, run by Fusion Pharmaceuticals Inc., active and no longer recruiting.
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a phase 2 interventional study registered as NCT06909825 by Fusion Pharmaceuticals Inc., with 85 participants planned, started 2025-02-26 and due to reach its primary completion in 2027-05. Interventions recorded: FPI-2265, Olaparib. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares FPI-2265, Metastatic castration-resistant prostate cancer, AstraZeneca, Prostate cancer.
Shares PARP inhibitors, Olaparib, Metastatic castration-resistant prostate cancer, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares FPI-2265, Metastatic castration-resistant prostate cancer, AstraZeneca, Prostate cancer.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares FPI-2265, AstraZeneca, Prostate cancer.
Shares PARP inhibitors, Olaparib, AstraZeneca.